- Home
- Fund
- Angel / Venture
- Vigil Neuroscience Completes $90 million Series B…
Vigil Neuroscience Completes $90 million Series B Financing to Advance a Pipeline of Microglia-targeted Medicines to Treat Rare and Common Neurodegenerative Diseases
Most Popular
Recent Posts
- Ravencoin Mining Economics September 5, 2023
- KKR to Present at the Bernstein 39th Annual Strategic Decisions Conference 2023 July 6, 2023
- Restaurant365 Announces $135M Funding Round Co-Led by KKR and L Catterton July 6, 2023
- KKR Names Dan Pietrzak Global Head of Private Credit July 6, 2023
- KREST Names Julia Butler As Chief Investment Officer July 6, 2023